LAL
Conditions
Brief summary
To evaluate the benefit of a precision medicine based strategy (targeted therapeutic options (TTOs)) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (in terms of composite remission).
Interventions
DRUGVenetoclax + Tofacitinib
Cycle 1: Venetoclax, 100 mg/d PO day1; 200 mg/d day2; 300 mg/d day3 and 400 mg/day thereafter (100 mg/day in case of concomitant administration of azoles) Tofacitinib, 10 mg BID PO started from day 5 Cycle 2 and 3 (4, 5 and 6 if applicable): Venetoclax, 400 mg/day PO (100 mg/day in case of concomitant administration of azoles) Tofacitinib, 10 mg BID PO
DRUGVenetoclax+ Everoliumus +Enrylaze
Cycle 1: Venetoclax, 100 mg/d PO day1; 200 mg/d day2; 300 mg/d day3 and 400 mg/day thereafter (100 mg/day in case of concomitant administration of azoles) Everolimus, 5 mg/day orally continuously. Everolimus must be administered at least 6 hours after venetoclax. Enrylaze 25 mg/m2 intravenously at day1, 3, 5, 7 (half dose for patients \>50 years) Cycle 2 and 3 (4, 5 and 6 if applicable): Venetoclax, 400 mg/day PO (100 mg/day in case of concomitant administration of azoles) Everolimus, 5 mg/day orally continuously (based on tolerance, in the absence of related AE \> 1, everolimus daily dose can be increased to 10 mg/d). Everolimus must be administered at least 6 hours after venetoclax. Enrylaze 25 mg/m2 intravenously at day1, 3, 5, 7 (half dose for patients \>50 years)
DRUGVenetoclax + 5 Azacitidine
Cycle 1: Venetoclax, 100 mg/day PO day1; 200 mg/d day2; 300 mg/d day3 and 400 mg/day thereafter (100 mg/d in case of concomitant administration of azoles) 5-azacytidine, 75 mg/m² sub cut QD started from day5 to day10 Cycle 2 and 3 (4, 5 and 6 if applicable): Venetoclax, PO 400 mg/day (100 mg/day in case of concomitant administration of azoles) 5-azacytidine, 75 mg/m² sub cut QD started from day1 to day7
Sponsors
Philippe ROUSSELOT
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 15y or more (under 18y only for France) 2. Signed informed consent for patients aged ≥ 18 years and signed informed consent from both parents for patients aged between ≥ 15 years and \< 18 years (only for France). 3. Patients with T-cell acute lymphoblastic leukemia in first or second relapse or in the refractory phase. 1. Patients with first relapses are eligible if relapse occurred within 24 months post complete remission achievement and if nelarabine is not considered as appropriate salvage therapy. 2. Patients with second and all subsequent relapses are eligible. 3. Refractory patients are defined as patients not responding after at least 2 lines of chemotherapy (induction + salvage). 4. Patients with relapses post-transplant and post CART-cells treatments are eligible. 4. Blast cells in blood and/or bone marrow to allow the shipment to one of the 3 reference laboratories in France, Spain and The Netherlands or An informative biological assessment already performed within 10 days prior to inclusion in one of the three reference laboratories in France, Spain or The Netherlands with at least one targeted therapeutic option validated (TTO1, venetoclax + tofacitinib; TTO2, venetoclax+ everolimus + enrylaze; TTO3, venetoclax + 5-azacytidine) by one of the three National Validation Committees. 5. Adequate ECOG score (0-3). 6. Patients must be affiliated to a National Health systems (see country-based specificity). 7. Patients must not have a contra-indication for venetoclax, tofacitinib, everolimus, glutaminolytic agents (enrylaze) or 5-azacytidine. 8. Willingness of women of child-bearing potential (WOCBP) or of male patients whose sexual partners are WOCBP to use an effective form of contraception during the study and at least 6 months thereafter.
Exclusion criteria
1. Patients in palliative care. 2. Patients with late relapses after the first complete remission (\> 24 months post complete remission). 3. Patients with extramedullary only relapses or with clinically symptomatic central nervous system (CNS) involvement. 4. Pregnant or lactating women. 5. Participation in another clinical trial with an investigative drug at the time of study enrolment. 6. Individuals with another active uncontrolled malignancy. 7. Known active HBV-, HCV and HIV related diseases. 8. Patient under curatorship or deprived of liberty (except for minors). 9. Patients with contra-indication to chemotherapy except if considered related to the ALL: * ASAT (SGOT) and/or ALAT (SGPT) \> 5 x ULN * Total bilirubin ≥ 2.5 x ULN * Estimated glomerular filtration rate (GFR) \< 50 mL/mn using the MDRD equation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission rate | 3 months | Composite Complete Remission (CRc) rate defined as complete remission (CR) and remission without complete hematological recovery (CRi) by 3 months post-randomization. |
Countries
Czechia, France, Germany, Netherlands, Poland, Spain
Contacts
CONTACTMelody FORT
CONTACTSandrine ROUX
Outcome results
None listed